Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open‐label, single‐arm, multicenter clinical study

The Relevant Outcome Scale for Alzheimer's disease (ROSA) is a novel, valid, and reliable instrument for multidimensional assessment of Alzheimer's disease (AD) symptoms across all severity stages. The ROSA and four standard instruments — the Alzheimer's disease Assessment Scale‐cognitive (ADAS‐cog), Severe Impairment Battery (SIB), Disability Assessment for Dementia (DAD), and the Neuropsychiatric Inventory (NPI) — were used in an open‐label, multicenter, single‐arm clinical study to assess treatment‐induced changes in cognitive, functional, and behavioral symptoms in patients with AD at different severity stages.

[1]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[2]  Frank Tennigkeit,et al.  Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice , 2011, Alzheimer's Research & Therapy.

[3]  Roy W Jones,et al.  Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials , 2007, Dementia and Geriatric Cognitive Disorders.

[4]  Pierre N Tariot,et al.  Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment , 2006, Neurology.

[5]  M. Borrie,et al.  Treatment Effect Size of Memantine Therapy in Alzheimer Disease and Vascular Dementia , 2006, Alzheimer disease and associated disorders.

[6]  M. Riepe,et al.  Memantine in Moderate-to-severe Alzheimer's Disease , 2006 .

[7]  P. Tariot,et al.  Meta-analysis of 6-month memantine clinical trials in Alzheimer’s disease , 2005, Alzheimer's & Dementia.

[8]  S. Gauthier,et al.  Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies , 2005, International journal of geriatric psychiatry.

[9]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[10]  S. Gauthier,et al.  Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. , 1999, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.

[11]  M. Mega,et al.  The Neuropsychiatric Inventory , 1994, Neurology.

[12]  P. Lachenbruch.  Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .

[13]  J. Saxton,et al.  Neuropsychological assessment of the severely impaired elderly patient. , 1989, Clinics in geriatric medicine.

[14]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[15]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.